Page last updated: 2024-12-05

fenbufen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fenbufen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It is a propionic acid derivative and acts by inhibiting the cyclooxygenase (COX) enzyme, which is involved in the production of prostaglandins, inflammatory mediators that contribute to pain, fever, and inflammation. Fenbufen was synthesized in the 1960s and was initially marketed for the treatment of rheumatoid arthritis and osteoarthritis. However, its use declined due to concerns about gastrointestinal toxicity and potential liver damage. Despite its limited clinical application, fenbufen remains a subject of research interest for its potential therapeutic effects in other areas. For instance, studies have investigated its potential as an anti-cancer agent, particularly in the treatment of breast cancer. Fenbufen is also being studied for its effects on the cardiovascular system and its potential role in the management of certain heart conditions. The research into fenbufen continues to explore its various pharmacological properties and potential applications in different therapeutic settings.'

fenbufen: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3335
CHEMBL ID277522
CHEBI ID31599
SCHEMBL ID25117
MeSH IDM0056461

Synonyms (151)

Synonym
AC-14459
MLS001074090
BB 0221124
AB00052195-13
BRD-K12513978-001-05-0
DIVK1C_000025
KBIO1_000025
3-(4-biphenylylcarbonyl)propionic acid
3-(4-phenylbenzoyl)propionic acid
cinopal
smr000059150
4-biphenyl-4-yl-4-oxobutanoic acid
lederfen
4-[1,1'-biphenyl-4-yl]-4-oxobutanoic acid
gamma-oxo(1,1'-biphenyl)-4-butanoic acid
CHEBI:31599 ,
cl-82204
MLS000069810 ,
4-(4-biphenylyl)-4-oxobutyric acid
butyric acid 4-(4-biphenyl)-4-oxo-
fenbufenum [inn-latin]
(1,1'-biphenyl)-4-butanoic acid, gamma-oxo-
propionic acid, 3-(4-biphenylylcarbonyl)-
bufemid
fenbufene [inn-french]
beta,p-phenylbenzoylpropionic acid
cl 82204
brn 2378560
einecs 252-979-0
diphenyl-4-gamma-oxo-gamma-butyric acid
napanol
3-(4-biphenylcarbonyl)propionic acid
SPECTRUM_001248
PRESTWICK2_000218
36330-85-5
fenbufen
PRESTWICK_567
NCGC00016834-01
cas-36330-85-5
SPECTRUM5_001528
PRESTWICK3_000218
BSPBIO_000235
BSPBIO_003140
IDI1_000025
AB00052195
D01344
fenbufen (jp17/usan/inn)
NCGC00094886-02
NCGC00094886-01
KBIOGR_000702
KBIO2_001728
KBIOSS_001728
KBIO2_006864
KBIO2_004296
KBIO3_002360
SPBIO_002156
PRESTWICK1_000218
SPBIO_001378
PRESTWICK0_000218
SPECTRUM2_001389
SPECTRUM3_001430
SPECTRUM4_000411
NINDS_000025
SPECTRUM1501008
BPBIO1_000259
NCGC00094886-03
4-(biphenyl-4-yl)-4-oxobutanoic acid
STK202178
HMS2092B03
HMS2090G14
4-[1,1''-biphenyl-4-yl]-4-oxobutanoic acid
bdbm50240374
gamma-oxo(1,1''-biphenyl)-4-butanoic acid
AKOS000200430
cl 82,204
nsc-757812
CHEMBL277522 ,
HMS500B07
HMS1921B13
HMS1568L17
4-oxo-4-(4-phenylphenyl)butanoic acid
SR-01000721906-5
sr-01000721906
HMS2095L17
pharmakon1600-01501008
nsc757812
tox21_110638
dtxsid9023043 ,
dtxcid703043
4-(4-biphenyl)-4-oxobutyric acid
HMS2235I24
S4526
CCG-38988
NCGC00016834-03
NCGC00016834-04
NCGC00016834-02
9815r1wr9b ,
fenbufene
nsc 757812
fenbufen [usan:inn:ban:jan]
3-10-00-03334 (beilstein handbook reference)
unii-9815r1wr9b
fenbufenum
4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid
cinopol
FT-0626394
HMS3372M18
fenbufen [ep monograph]
fenbufen [who-dd]
(1,1'-biphenyl)-4-butanoic acid, .gamma.-oxo-
fenbufen [mart.]
fenbufen [jan]
fenbufen [mi]
fenbufen [inn]
fenbufen [usan]
SCHEMBL25117
tox21_110638_1
NCGC00016834-07
SS-4225
CS-4743
3-(4-biphenylylcarbonyl)-propionic acid
4-biphenyl-4-yl-4-oxobutyric acid
4-biphenyl-4-yl-4-oxo-butyric acid
3-(4'-biphenylcarbonyl) propanoic acid
HY-B1138
.beta.,p-phenylbenzoylpropionic acid
diphenyl-4-.gamma.-oxo-.gamma.-butyric acid
.gamma.-oxo(1,1'-biphenyl)-4-butanoic acid
4-[1,1'-biphenyl]-4-yl-4-oxobutanoic acid #
[1,1'-biphenyl]-4-butanoic acid, .gamma.-oxo-
AB00052195_14
OPERA_ID_464
mfcd00056701
DB08981
SR-01000721906-4
SR-01000721906-2
fenbufen, 96%
fenbufen, analytical standard
fenbufen, european pharmacopoeia (ep) reference standard
SBI-0051631.P002
HMS3712L17
Z99599540
3-(4-phenyl)benzoyl propionic acid
fenbufen,(s)
Q2304195
BCP12106
BRD-K12513978-001-16-7
HMS3885N06
fenbufen 100 microg/ml in acetonitrile
4-([1,1'-biphenyl]-4-yl)-4-oxobutanoicacid
EN300-14196

Research Excerpts

Overview

Fenbufen (Cinopal) is an orally active nonsteroidal anti-inflammatory drug with analgesic and antipyretic activity. Fenbufen appears to be a pro-drug capable of circumventing some gastric toxicity.

ExcerptReferenceRelevance
"Fenbufen is an arylpropionic acid derivative belonging to the group of non-steroidal anti-inflammatory drugs (NSAIDs). "( Inhibition of ATP synthesis by fenbufen and its conjugated metabolites in rat liver mitochondria.
Hansen, SH; Skonberg, C; Syed, M, 2016
)
2.16
"Fenbufen is a non-selective non-steroidal anti-inflammatory drug (NSAID), used to treat acute and chronic painful conditions. "( Single dose oral fenbufen for acute postoperative pain in adults.
Derry, S; McQuay, HJ; Moore, RA, 2009
)
2.14
"Fenbufen (Cinopal) is an orally active nonsteroidal anti-inflammatory drug with analgesic and antipyretic activity. "( Pharmacologic properties of fenbufen.
Kerwar, SS, 1983
)
2
"Fenbufen thus appears to be a pro-drug capable of circumventing at least some of the gastric toxicity usually incurred when compounds, which are themselves capable of inhibiting PG synthesis, are introduced directly into the stomach."( The pharmacological properties of fenbufen. A review.
Osterberg, AC; Panagides, J; Sloboda, AE; Tolman, EL, 1980
)
1.26
"Fenbufen is a phenylalkanoic acid derivative with analgesic and anti-inflammatory activity. "( Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1981
)
3.15
"Fenbufen is an analgesic, antipyretic and anti-inflammatory drug that is characterized by poor water solubility, a defect increased by very low wettability. "( Improved dissolution behavior of fenbufen by spherical crystallization.
Barthélémy, C; Di Martino, P; Joiris, E; Martelli, S; Palmieri, GF; Piva, F, 1999
)
2.03

Effects

Fenbufen (Cinopal) has been evaluated extensively in 155 clinical trials, including 102 in rheumatoid arthritis and 53 in osteoarthritis. Fenbufen has a long duration of anti-inflammatory and analgesic activity.

ExcerptReferenceRelevance
"Fenbufen has a long duration of anti-inflammatory and analgesic activity."( Pharmacologic properties of fenbufen.
Kerwar, SS, 1983
)
1.28
"Fenbufen (Cinopal) has been evaluated extensively in 155 clinical trials, including 102 in rheumatoid arthritis and 53 in osteoarthritis. "( Overview of efficacy of fenbufen in rheumatoid arthritis and osteoarthritis.
Bernstein, J, 1983
)
2.02
"Fenbufen has a long duration of anti-inflammatory and analgesic activity."( Pharmacologic properties of fenbufen.
Kerwar, SS, 1983
)
1.28

Treatment

The fenbufen-treated group showed significant improvement in four parameters: pain at rest, pain on movement, duration of pain, and number of swollen joints. Fenbufen pretreatment was shown to have no significant effect on ciprofloxacin pharmacokinetics.

ExcerptReferenceRelevance
"The fenbufen-treated group showed significant improvement in four parameters: pain at rest, pain on movement, duration of pain, and number of swollen joints."( A six-month parallel group comparison of fenbufen and naproxen in the treatment of rheumatoid arthritis.
Khan, FM, 1983
)
1.01
"Fenbufen-treated patients, however, reported fewer occurrences (4) of severe drug-related adverse experiences than indomethacin-treated patients (20)."( Long-term, double-blind randomized parallel group studies comparing fenbufen and indomethacin in patients with osteoarthritis.
Reid, RT; Salzman, RT, 1982
)
1.22
"Fenbufen pretreatment was shown to have no significant effect on ciprofloxacin pharmacokinetics."( Lack of a pharmacokinetic interaction between ciprofloxacin and fenbufen.
Kamali, F, 1994
)
1.25
"3. Fenbufen treatment alone tended to lower rectal temperature."( Effect of the cyclo-oxygenase inhibitor fenbufen on muscle and liver protein metabolism, muscle glutamine and plasma insulin in endotoxaemic rats.
Jepson, MM; Millward, DJ, 1989
)
1.06

Toxicity

ExcerptReferenceRelevance
" Detailed analysis of all reported adverse effects demonstrated that fenbufen is a relatively safe nonsteroidal anti-inflammatory drug."( Side effect and safety data for fenbufen.
Crossley, RJ, 1983
)
0.78

Pharmacokinetics

The plasma concentration-time profiles and serum protein binding of enoxacin, fenbufen and its active metabolite, felbinac, were investigated in rats. The pharmacokinetic analysis based on the physiological model indicated that fen bufen did not affect the permeability across the blood-brain or blood-CSF barrier. Coadministered fenbuffen significantly prolonged the plasma elimination half-life of ciprofloxacins from 40 to 50 hours.

ExcerptReferenceRelevance
" The half-life of plasma disappearance was 10."( Pharmacokinetics of fenbufen in man.
Belkahia, C; Cuisinaud, G; Legheand, J; Lejeune, E; Llorca, G; Sassard, J, 1979
)
0.58
" The pharmacokinetic analysis based on the physiological model indicated that fenbufen did not affect the permeability across the blood-brain or blood-CSF barrier."( Effect of fenbufen on the pharmacokinetics of sparfloxacin in rats.
Iwamoto, K; Katagiri, Y; Naora, K; Sekine, Y; Tanaka, K; Yamaguchi, T, 1992
)
0.91
" Coadministered fenbufen significantly prolonged the plasma elimination half-life of ciprofloxacin from 40."( A possible reduction in the renal clearance of ciprofloxacin by fenbufen in rats.
Hayashibara, M; Ichikawa, N; Iwamoto, K; Katagiri, Y; Naora, K, 1990
)
0.86
"In order to clarify the possibility of pharmacokinetic interaction between quinolone and fenbufen, the plasma concentration-time profiles and serum protein binding of enoxacin, fenbufen and its active metabolite, felbinac, were investigated in rats."( A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats.
Hayashibara, M; Ichikawa, N; Iwamoto, K; Katagiri, Y; Naora, K, 1990
)
0.73
"The possible pharmacokinetic interaction between a new quinolone and fenbufen was investigated by comparing the plasma concentration-time profiles and serum protein binding of ofloxacin, fenbufen and its active metabolite, felbinac, in rats."( Absence of pharmacokinetic interaction between ofloxacin and fenbufen in rats.
Hayashibara, M; Ichikawa, N; Iwamoto, K; Katagiri, Y; Naora, K, 1989
)
0.75

Compound-Compound Interactions

The effects of enoxacin, a new quinolone antibacterial agent, and its combination with 4-biphenylacetate (BPA) were examined on population spikes induced by electrical stimulation of the stratum radiatum in the CA1 pyramidal cell layer in rat hippocampal slices. The neurotoxicity of p-toluenesulfonate hydrate (T-3262), which is a new PCA, was investigated in mice in a combination with fenbufen (FBF)

ExcerptReferenceRelevance
"The effects of enoxacin, a new quinolone antibacterial agent, and its combination with 4-biphenylacetate (BPA), an active metabolite of the non-steroidal antiinflammatory agent fenbufen, were examined on population spikes induced by electrical stimulation of the stratum radiatum in the CA1 pyramidal cell layer in rat hippocampal slices."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.7
"Comparing with other pyridonecarboxylic acids (PCAs), the neurotoxicity of (+/-)-7-(3-amino-1-pyrrolidinyl)-6-fluoro-1-(2,4-difluorophenyl)-1,4- dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid p-toluenesulfonate hydrate (T-3262), which is a new PCA, was investigated in mice in a combination with fenbufen (FBF)."( [Adverse drug interactions between pyridonecarboxylic acids and nonsteroidal antiinflammatory drugs: convulsion after oral or intracerebral administration in mice].
Hirai, S; Makino, S; Narita, H; Tanaka, K, 1989
)
0.45

Bioavailability

ExcerptReferenceRelevance
" The procedures are suitable for bioavailability and pharmacokinetic studies."( Quantitation of the anti-inflammatory agent fenbufen and its metabolites in human serum and urine using high-pressure liquid chromatography.
Barr, A; Bonenfant, PA; Chiccarelli, FS; Van Lear, GE, 1978
)
0.52
" The dissolution rate and bioavailability of FB were significantly increased by the formation of inclusion complexes (alpha greater than gamma-CyD complex)."( Improvement of oral bioavailability of fenbufen by cyclodextrin complexations.
Acartürk, F; Imai, T; Inoue, Y; Miyaji, T; Otagiri, M; Uekama, K, 1992
)
0.55
" The relative bioavailability of the SWCNT-MIP composites (F %) displayed the highest value of 143."( Green Synthesis of Carbon Nanotubes-Reinforced Molecularly Imprinted Polymer Composites for Drug Delivery of Fenbufen.
Chai, MH; He, W; Huang, YP; Liu, XL; Liu, ZS; Yao, HF, 2018
)
0.69
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

In varying proportions, a total of 11 metabolites (including those listed above) together with fenbufen itself were isolated and characterized from the urine of mice, rats, guinea pigs, dogs and/or monkeys. In addition, dose-response derived potencies show fen bufen more potent than ASA and at least as potent as phenylbutazone in all five tests.

ExcerptRelevanceReference
" In addition, dose-response derived potencies show fenbufen more potent than aspirin and at least as potent as phenylbutazone in all five tests."( Fenbufen, a new anti-inflammatory analgesic: synthesis and structure-activity relationships of analogs.
Child, RG; Osterberg, AC; Sloboda, AE; Tomcufcik, AS, 1977
)
1.95
" Although treatment with each quinolone or fenbufen alone at a dosage level tested in mice showed no changes, coadministration of a large dose of all quinolones and fenbufen caused convulsant death."( Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice.
Akahane, K; Furuhama, K; Takayama, S; Tawara, K, 1992
)
0.78
" The dose-response relationships showed that the effect of enoxacin was 100 times potentiated in the presence of BPA (10(-5) M)."( Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.
Hori, S; Ito, T; Kadokawa, T; Miura, Y; Miyahara, T; Shimada, J, 1991
)
0.5
"01) differences in microbleeding between subjects given aspirin and those given either dosage of fenbufen or placebo."( Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, and placebo.
Lebel, E; Lussier, A; Tétreault, L, 1983
)
0.72
" In varying proportions, a total of 11 metabolites (including those listed above) together with fenbufen itself were isolated and characterized from the urine of mice, rats, guinea pigs, dogs and/or monkeys dosed with fenbufen."( Disposition and metabolism of fenbufen in several laboratory animals.
Chiccarelli, FS; Eisner, HJ; Van Lear, GE, 1980
)
0.77
" In addition, dose-response derived potencies show fenbufen more potent than ASA and at least as potent as phenylbutazone in all five tests."( A new non-steroidal anti-inflammatory analgesic: gamma-oxo (1,1'-biphenyl)-4-butanoic acid (fenbufen). Chemistry and activity of analogs.
Child, RG; Osterberg, AC; Sloboda, AE; Tomcufcik, AS, 1980
)
0.73
" Steady state serum concentrations were reached within a week with multiple dosing regimens."( Metabolic and pharmacokinetic studies with fenbufen in man.
Chiccarelli, FS; Eisner, HJ; Van Lear, GE, 1980
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
4-oxo monocarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency6.59020.007215.758889.3584AID1224835; AID588342; AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency12.38450.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency19.50170.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency25.92900.004110.890331.5287AID504467
SMAD family member 3Homo sapiens (human)Potency19.50170.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency5.30800.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.69050.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743042; AID743053; AID743054
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency26.60320.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency11.23710.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.84130.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency34.67130.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency8.91250.28189.721235.4813AID2326
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency12.68250.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.38220.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency14.55340.001530.607315,848.9004AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.70380.000229.305416,493.5996AID1259244; AID743075; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
activating transcription factor 6Homo sapiens (human)Potency5.35380.143427.612159.8106AID1159516
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
histone deacetylase 9 isoform 3Homo sapiens (human)Potency14.14670.037617.082361.1927AID1259364; AID1259388
ras-related protein Rab-9AHomo sapiens (human)Potency5.62340.00022.621531.4954AID485297
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency7.07950.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.58660.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency9.43920.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency9.43920.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseHomo sapiens (human)Ki360.00000.00000.37564.9000AID1660990
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)3.90000.00032.177410.0000AID432204
Sodium/hydrogen exchanger 1Rattus norvegicus (Norway rat)IC50 (µMol)3.90000.01000.64613.9000AID432204
Caspase-1Homo sapiens (human)IC50 (µMol)1.56000.00201.70138.8000AID1802657
Caspase-3Homo sapiens (human)IC50 (µMol)1.56000.00021.19798.8000AID1802657
Caspase-4Homo sapiens (human)IC50 (µMol)1.56000.30002.26418.8000AID1802657
Caspase-5Homo sapiens (human)IC50 (µMol)1.56000.30002.23588.8000AID1802657
Caspase-9Homo sapiens (human)IC50 (µMol)1.56000.30002.26418.8000AID1802657
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)8.10000.00101.453910.0000AID432205
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (106)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayCaspase-3Homo sapiens (human)
luteolysisCaspase-3Homo sapiens (human)
response to hypoxiaCaspase-3Homo sapiens (human)
B cell homeostasisCaspase-3Homo sapiens (human)
negative regulation of cytokine productionCaspase-3Homo sapiens (human)
proteolysisCaspase-3Homo sapiens (human)
apoptotic processCaspase-3Homo sapiens (human)
DNA damage responseCaspase-3Homo sapiens (human)
axonal fasciculationCaspase-3Homo sapiens (human)
heart developmentCaspase-3Homo sapiens (human)
sensory perception of soundCaspase-3Homo sapiens (human)
learning or memoryCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressCaspase-3Homo sapiens (human)
response to xenobiotic stimulusCaspase-3Homo sapiens (human)
response to UVCaspase-3Homo sapiens (human)
response to woundingCaspase-3Homo sapiens (human)
response to glucoseCaspase-3Homo sapiens (human)
response to X-rayCaspase-3Homo sapiens (human)
regulation of macroautophagyCaspase-3Homo sapiens (human)
protein processingCaspase-3Homo sapiens (human)
hippocampus developmentCaspase-3Homo sapiens (human)
protein catabolic processCaspase-3Homo sapiens (human)
erythrocyte differentiationCaspase-3Homo sapiens (human)
platelet formationCaspase-3Homo sapiens (human)
negative regulation of B cell proliferationCaspase-3Homo sapiens (human)
regulation of protein stabilityCaspase-3Homo sapiens (human)
response to cobalt ionCaspase-3Homo sapiens (human)
response to estradiolCaspase-3Homo sapiens (human)
response to lipopolysaccharideCaspase-3Homo sapiens (human)
glial cell apoptotic processCaspase-3Homo sapiens (human)
response to tumor necrosis factorCaspase-3Homo sapiens (human)
response to nicotineCaspase-3Homo sapiens (human)
response to hydrogen peroxideCaspase-3Homo sapiens (human)
T cell homeostasisCaspase-3Homo sapiens (human)
response to amino acidCaspase-3Homo sapiens (human)
fibroblast apoptotic processCaspase-3Homo sapiens (human)
cell fate commitmentCaspase-3Homo sapiens (human)
negative regulation of cell cycleCaspase-3Homo sapiens (human)
negative regulation of activated T cell proliferationCaspase-3Homo sapiens (human)
striated muscle cell differentiationCaspase-3Homo sapiens (human)
response to glucocorticoidCaspase-3Homo sapiens (human)
neuron apoptotic processCaspase-3Homo sapiens (human)
protein maturationCaspase-3Homo sapiens (human)
anterior neural tube closureCaspase-3Homo sapiens (human)
pyroptosisCaspase-3Homo sapiens (human)
leukocyte apoptotic processCaspase-3Homo sapiens (human)
cellular response to staurosporineCaspase-3Homo sapiens (human)
apoptotic signaling pathwayCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-3Homo sapiens (human)
execution phase of apoptosisCaspase-3Homo sapiens (human)
positive regulation of pyroptosisCaspase-3Homo sapiens (human)
positive regulation of amyloid-beta formationCaspase-3Homo sapiens (human)
epithelial cell apoptotic processCaspase-3Homo sapiens (human)
keratinocyte differentiationCaspase-3Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-3Homo sapiens (human)
neuron differentiationCaspase-3Homo sapiens (human)
proteolysisCaspase-4Homo sapiens (human)
inflammatory responseCaspase-4Homo sapiens (human)
protein autoprocessingCaspase-4Homo sapiens (human)
defense response to bacteriumCaspase-4Homo sapiens (human)
innate immune responseCaspase-4Homo sapiens (human)
regulation of inflammatory responseCaspase-4Homo sapiens (human)
positive regulation of inflammatory responseCaspase-4Homo sapiens (human)
defense response to Gram-positive bacteriumCaspase-4Homo sapiens (human)
protein maturationCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCaspase-4Homo sapiens (human)
pyroptosisCaspase-4Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-4Homo sapiens (human)
non-canonical inflammasome complex assemblyCaspase-4Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-4Homo sapiens (human)
cellular response to amyloid-betaCaspase-4Homo sapiens (human)
positive regulation of interleukin-18-mediated signaling pathwayCaspase-4Homo sapiens (human)
apoptotic processCaspase-4Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-4Homo sapiens (human)
proteolysisCaspase-5Homo sapiens (human)
substantia nigra developmentCaspase-5Homo sapiens (human)
protein maturationCaspase-5Homo sapiens (human)
cellular response to mechanical stimulusCaspase-5Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-5Homo sapiens (human)
apoptotic processCaspase-5Homo sapiens (human)
positive regulation of inflammatory responseCaspase-5Homo sapiens (human)
response to hypoxiaCaspase-9Homo sapiens (human)
kidney developmentCaspase-9Homo sapiens (human)
response to ischemiaCaspase-9Homo sapiens (human)
apoptotic processCaspase-9Homo sapiens (human)
DNA damage responseCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome cCaspase-9Homo sapiens (human)
protein processingCaspase-9Homo sapiens (human)
platelet formationCaspase-9Homo sapiens (human)
response to cobalt ionCaspase-9Homo sapiens (human)
response to estradiolCaspase-9Homo sapiens (human)
response to lipopolysaccharideCaspase-9Homo sapiens (human)
glial cell apoptotic processCaspase-9Homo sapiens (human)
cellular response to UVCaspase-9Homo sapiens (human)
signal transduction in response to DNA damageCaspase-9Homo sapiens (human)
positive regulation of apoptotic processCaspase-9Homo sapiens (human)
fibroblast apoptotic processCaspase-9Homo sapiens (human)
neuron apoptotic processCaspase-9Homo sapiens (human)
protein maturationCaspase-9Homo sapiens (human)
cellular response to dexamethasone stimulusCaspase-9Homo sapiens (human)
leukocyte apoptotic processCaspase-9Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-9Homo sapiens (human)
epithelial cell apoptotic processCaspase-9Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-9Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
protease bindingCaspase-3Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityCaspase-3Homo sapiens (human)
death receptor bindingCaspase-3Homo sapiens (human)
protein bindingCaspase-3Homo sapiens (human)
peptidase activityCaspase-3Homo sapiens (human)
phospholipase A2 activator activityCaspase-3Homo sapiens (human)
protein-containing complex bindingCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-3Homo sapiens (human)
enzyme activator activityCaspase-3Homo sapiens (human)
lipopolysaccharide bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-4Homo sapiens (human)
protein bindingCaspase-4Homo sapiens (human)
lipid bindingCaspase-4Homo sapiens (human)
CARD domain bindingCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-4Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-5Homo sapiens (human)
protein bindingCaspase-5Homo sapiens (human)
cysteine-type peptidase activityCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-5Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-9Homo sapiens (human)
protein bindingCaspase-9Homo sapiens (human)
enzyme activator activityCaspase-9Homo sapiens (human)
peptidase activityCaspase-9Homo sapiens (human)
SH3 domain bindingCaspase-9Homo sapiens (human)
protein kinase bindingCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-9Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
cytoplasmCaspase-3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
nucleoplasmCaspase-3Homo sapiens (human)
cytosolCaspase-3Homo sapiens (human)
neuronal cell bodyCaspase-3Homo sapiens (human)
death-inducing signaling complexCaspase-3Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
extracellular regionCaspase-4Homo sapiens (human)
mitochondrionCaspase-4Homo sapiens (human)
endoplasmic reticulumCaspase-4Homo sapiens (human)
endoplasmic reticulum membraneCaspase-4Homo sapiens (human)
cytosolCaspase-4Homo sapiens (human)
plasma membraneCaspase-4Homo sapiens (human)
protein-containing complexCaspase-4Homo sapiens (human)
non-canonical inflammasome complexCaspase-4Homo sapiens (human)
cytoplasmCaspase-4Homo sapiens (human)
NLRP1 inflammasome complexCaspase-4Homo sapiens (human)
cytosolCaspase-5Homo sapiens (human)
NLRP1 inflammasome complexCaspase-5Homo sapiens (human)
cytoplasmCaspase-5Homo sapiens (human)
mitochondrionCaspase-9Homo sapiens (human)
nucleusCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
caspase complexCaspase-9Homo sapiens (human)
apoptosomeCaspase-9Homo sapiens (human)
protein-containing complexCaspase-9Homo sapiens (human)
cytosolCaspase-9Homo sapiens (human)
cytoplasmCaspase-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (114)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1494124Antibacterial activity against Norfloxacin-resistant Staphylococcus aureus 1199B over-expressing NorA after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1494123Antibacterial activity against methicillin-resistant Staphylococcus aureus NCTC 13373 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID432204Inhibition of ovine COX1 by enzyme-immuno assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID1494128Antibacterial activity against Escherichia coli NCTC 12241 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1744121Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID432203Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX22009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID578611Cytotoxicity against human A549 cells after 2 days by MTT assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries.
AID578612Cytotoxicity against human MCF7 cells after 2 days by MTT assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries.
AID1494121Antibacterial activity against Bacillus subtilis NCTC 10400 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1660990Inhibition of human DHFR in presence of DHF and NADPH by UV-vis spectrometry by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase.
AID432205Inhibition of ovine COX2 by enzyme-immuno assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID414245Displacement of [3H]NCS-382 from GABAB receptor in rat brain homogenate2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Novel high-affinity and selective biaromatic 4-substituted gamma-hydroxybutyric acid (GHB) analogues as GHB ligands: design, synthesis, and binding studies.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID432207Analgesic activity in albino mouse inhibition of acetic acid-induced writhing response at 10 mg/kg, po2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1744122Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1494126Antibacterial activity against Staphylococcus aureus EMRSA-15 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID432206Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID24263Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of N,N-diethylglycolamide ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID24265Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of methyl ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1494127Antibacterial activity against tetracycline/methicillin-resistant Staphylococcus aureus XU212 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID578613Cytotoxicity against mouse TRAMP-C1 cells after 2 days by MTT assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID432209Inhibition of lipid peroxidation assessed as malondialdehyde level per 100 mg of gastric mucosa isolated from albino mouse at dose 30 mg/kg, po2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1494120Antibacterial activity against Enterococcus faecalis NCTC 12697 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID578614Cytotoxicity against mouse C26 cells after 2 days by MTT assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries.
AID183692Evaluated for the percentage inhibition by adjuvant arthritis test at a dose of 50 mg/kg administarted perorally1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Replacement of aromatic or heteroaromatic groups in nonsteroidal antiinflammatory agents with the ferrocene group.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1494122Antibacterial activity against methicillin-sensitive Staphylococcus aureus NCTC 12981 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID1494125Antibacterial activity against erythromycin-resistant Staphylococcus aureus RN4220 after 16 hrs by microdilution method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
AID432208Gastrointestinal toxicity in albino mouse assessed as ulcerogenic indicates at dose 30 mg/kg, po2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802657Caspase Catalytic Activity Assay from Article 10.1016/j.chembiol.2017.02.003: \\Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.\\2017Cell chemical biology, Mar-16, Volume: 24, Issue:3
Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (211)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990113 (53.55)18.7374
1990's41 (19.43)18.2507
2000's16 (7.58)29.6817
2010's28 (13.27)24.3611
2020's13 (6.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.15 (24.57)
Research Supply Index5.55 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index59.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials32 (14.35%)5.53%
Reviews9 (4.04%)6.00%
Case Studies21 (9.42%)4.05%
Observational0 (0.00%)0.25%
Other161 (72.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]